Smithkline Beecham Biologicals S.a.

Smithkline Beecham Biologicals

Pierre Hauser

Pierre Desmons

Pierre Voet

Nathalie Marie-Josephe Claude Garcon-Johnson

Clothilde Thiriart

Nathalie Marie-Josephe Garcon

Moncef Mohamed Slaoui

Julien Peetermans

Nathalie Marie-Josephe Garcon-Johnson

Nathalie Marie-Josephe Claude Garcon

Jean Petre

Moncef Slaoui

A vaccine formulation for the treatment or prophylaxis of hepatitis, especially hepatitis, especially hepatitis B, infections is provided comprising the hepatitis antigen and a suitable carrier such as alum in combination with 3-O-deacylated monophosphoryl lipid. A combination vaccines including the vaccine formulation are also described.

Hepatitis vaccines containing 3-O-deacylated monophoshoryl lipid A

The invention relates to a vaccine formulation for the prevention of Haemophilus Influenzae Type B (Hib) infections and where the antigen is adsorbed onto aluminum phosphate. The invention also relates to a multivalent vaccines, that is a vaccine for the amelioration or treatment of more than one disease states. The present invention also relates to the production and use of such vaccines in medicine.

Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminum phosphate

A vaccine formulation for the treatment or prophylaxis of hepatitis, especially hepatitis B, infections is provided comprising the hepatitis antigen and a suitable carrier such as alum in combination with 3-O-deacylated monophosphoryl lipid A. Combination vaccines including the vaccine formulation are also described.

Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A

A novel vaccine formulation is provided, comprising a hepatitis B component, particularly hepatitis B surface antigen, in combination with aluminum phosphate and 3 de-O-acylated monophosphoryl lipid A.

Hepatitis B vaccine

Stable and effective multivalent vaccine compositions comprising Hepatitis B surface antigen (HBsAg) are described wherein the HBsAg component is stable for one week at 37.degree. C. and is highly immunogenic, for example when the vaccine is administered to infants. The compositions typically comprise HBsAg adsorbed to aluminium phosphate and other antigens, especially those suitable for use in a paediatric vaccine, adsorbed to aluminium phosphate or aluminium hydroxide. Methods for preparing the vaccines and the use of aluminium phosphate to stabilise HBsAg in a multivalent vaccine formulation are also described.

Vaccine

Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A

Growing community of inventors

Chaumont-Gistoux, Belgium

Pierre Hauser